Compounds which inhibit leukocyte adhesion mediated by VLA-4

Details Compounds which inhibit leukocyte adhesion mediated by VLA-4 Compounds which inhibit leukocyte adhesion mediated by VLA-4

2005-09-27

2005-09-27

Richter, Johann (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S408000, C546S208000, C546S210000, C548S253000, C548S542000

Reexamination Certificate

active

06949570

ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4743614 (1988-05-01), Terano
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 6180116 (2001-01-01), Phillippe
patent: 6436904 (2002-08-01), Ashwell et al.
patent: 2241149 (1977-07-01), None
patent: 2259224 (1978-01-01), None
patent: 26 55 636 (1977-06-01), None
patent: 195 48 709 (1997-07-01), None
patent: 196 54 483 (1998-01-01), None
patent: 19713000 (1999-10-01), None
patent: 0 147 211 (1985-07-01), None
patent: 0 228 176 (1988-10-01), None
patent: 0 330 506 (1989-08-01), None
patent: 0 330 506 (1989-08-01), None
patent: 0 526 348 (1993-02-01), None
patent: 0 535 521 (1993-04-01), None
patent: 92/16549 (1992-10-01), None
patent: 93/12809 (1993-07-01), None
patent: 96/01644 (1996-01-01), None
patent: 96/22966 (1996-08-01), None
patent: 97/23451 (1997-07-01), None
patent: 98/00395 (1998-01-01), None
patent: 98/33783 (1998-08-01), None
patent: 98/53817 (1998-12-01), None
patent: 99/06390 (1999-02-01), None
patent: 99/06391 (1999-02-01), None
patent: 99/06431 (1999-02-01), None
patent: 99/06432 (1999-02-01), None
patent: 99/06433 (1999-02-01), None
patent: 99/10312 (1999-03-01), None
patent: 99/10313 (1999-03-01), None
patent: 99/37605 (1999-07-01), None
patent: 99/37618 (1999-07-01), None
Sturzebecher Thrombosis Research 54, 245-52 1989.
Abraham, W.M., et al. “α-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clim. Invest.93: 776-787 (1994).
Advani, S.B., et al. “Potential Antineoplastic Agents: N-(2-Benzoxazolyl)amino Acid Esters.”J. of Pharm. Sci.57(10): 1693-1696 (1968).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff.52: 239-246 (1993).
Baron, J.L., et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma.”J. Exp. Med.177: 57-68 (1993).
Baron, J.L., et al. “The Pathogenesis of Adeoptive Murine Autoimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest.93: 1700-1708 (1994).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin.”Diabetes.43: 529-534 (1994).
Cybulsky, M.I., et al. “Endotherlial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis.”Science.251: 788-791 (1991).
Elices, M.J., et al. “Expression and Functional Significance of Alternatively Spliced CSI Fibronectin in Rheumatoid Arthritis Miscrovasculature.”J. Clin. Invest.93: 405-416 (1994).
Elices, M.J., et al. “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site District from the CLA-4/Fibronectin Binding Site.”Cell.60: 577-584 (1990).
Gordeev, M.F. “Combinatorial Approaches to pharmacophoric Heterocycles: A Solid-Phase Synthesis of 3,1-Benzoxazine-4-ones.”Biotech. and Bioengineering.61(1): 13-16 (1998).
Hamann, A., et al. “Role of α4-Integrins in Lymphocyte Homing to Mucosal Tissues in Vivo.”J. Immunology.152: 3283-3292 (1994).
Henke, B.R., et al. “N-(2-Benzoylphenyl)-L-tyrosine :Aryl Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents.”J. Med. Chem.41(25): 5020-5036 (1998).
Hladon, B., et al. “In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines.”Arch. Immunol. Ther. Exp.40(2): 145-150 (1992) (Abstract).
Hoffman, S., et al. “N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids.”Z. Chem.12(1): 21-22 (1972), CODEN: ZECEAL (Abstract).
Kawaguchi, S., et al. “VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface.”Japanese J. Cancer Res.83: 1304-1316 (1992).
Lauri, D., et al. “Decreased adhesion to endothelial cells and matrix proteins of H-2Kbgene transfected tumour cells.”British J. Cancer.68: 862-867 (1993).
Lazer, E.S., et al. “Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action.”J. Med. Chem.37(7): 913-923 (1994).
Li, H., et al. “An Atherogenic Diet Rapitdly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leukocyte Adhesion Molecule, in Rabbit Aortic Endothelium.”Arterioscler. Thromb.13(2): 197-204 (1993).
Ma, D., et al. “Accelerating Effect Induced by the Structure of a-Amino Acid in the Copper Catalyzed Coupling Reaction of Aryl Halides with a-Amino Acids. Synthesis of Benzolactam-V8.”J. Am. Chem. Soc.120(48): 12459-12467 (1998).
Mulligan, M.S., et al. “Role of β1, β2 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes.”J. Immunol.150(6): 2407-2417 (1993).
Osborn, L. “Leukocyte Adhesion to Endothelium in Inflammation.”Cell.62: 3-6 (1990).
Paavonen, T., et al. “In Vivo Evidence of the Role of α4β1-VCAM-1 Interaction in Sarcoma, but not in Carcinoma Extravasation.”Int. J. Can.58: 298 (1994).
Paul, L.C., et al. “Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts.”Transp. Proceed.25(1): 813-814 (1993).
Pretolani, M., et al. “Antibody to Very Late Activation Antigen 4 Prevents Antigen-induced Bronchial Hyperreactivity and Cellular Infiltration in the Guinea Pig Airways.”J. Exp. Med.180: 795-805 (1994).
Sasserville, V.G., et al. “Monocyte Adhesion to Endothelium in Simian Immunodeficiency Virus-Induced AIDS Encephalitis is Mediated by Vascular Cell Adhesion Molecule-1/α4β1Integrin Interactions.”Am. J. Path.144(1): 27-40 (1994).
Schadendorf, D., et al. “Tumour Progression and Metastatic Behaviour In Vivo Corre

Affiliated with

Also associated with

Rating

Compounds which inhibit leukocyte adhesion mediated by VLA-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds which inhibit leukocyte adhesion mediated by VLA-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds which inhibit leukocyte adhesion mediated by VLA-4 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3416946